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doi:10.1016/j.jtcvs.2003.10.034Objectives: Bleeding and inflammation are major complications of extracorporeal
circulation. Off-pump coronary artery bypass grafting may reduce the rate of
complications, but it can only be applied in selected cases. Pilot studies have shown
a potential benefit from the use of antifibrinolytic drugs, but efficacy in randomized
double-blind studies evaluating off- and on-pump coronary artery bypass grafting
has not been proved.
Methods: We enrolled 102 patients scheduled for on-pump (n  51) or off-pump (n
 51) coronary artery bypass grafting. Patients were separately double-blind ran-
domly assigned to treatment with tranexamic acid (1 g as 20-minute bolus before
skin incision, followed by continuous infusion of 400 mg/h, with 500 mg added to
priming in patients undergoing on-pump coronary artery bypass grafting) or placebo
(saline solution of equivalent volume). Bleeding in the first 24 postoperative hours
was the primary outcome. Requirement for allogeneic transfusions, thrombotic
complications, outcomes, and monitoring of coagulation, fibrinolysis, and inflam-
mation were also recorded.
Results: Tranexamic acid reduced total postoperative bleeding by 43% in patients
undergoing on-pump coronary artery bypass grafting and by 27% in those under-
going off-pump coronary artery bypass grafting (P .0001), with 80% reduction in
bleeding exceeding 600 mL (P  .001), 58% reduction in the requirement for all
allogeneic transfusions (P  .07), and no apparent effect on thrombotic complica-
tions or outcome. This was associated with a reduction in plasma D-dimer levels (P
 .0001), to a greater degree in patients undergoing on-pump coronary artery
bypass grafting (P  .0001), and interleukin 6 levels (P  .0001), to a greater
degree in patients undergoing off-pump coronary artery bypass grafting (P  .001).
Conclusions: By affecting fibrinolysis, tranexamic acid significantly reduces bleed-
ing both in off- and on-pump coronary artery bypass grafting and may modulate
inflammation in these surgical settings.
At present most cardiac surgery is performed with extracorporealcirculation. Excessive perioperative bleeding is most commonamong the well-known complications of cardiopulmonary bypass(CPB).1 Activation and consumption of platelets, activation of theintrinsic and extrinsic pathways of coagulation, and hyperfibrin-olysis are all involved in the relatively frequent hemorrhagic
2-4diathesis seen in cardiac surgery. In addition, inflammation, albeit rarely leading
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CSPto clinically relevant organ dysfunction, may affect the
outcome of patients undergoing coronary artery bypass
grafting (CABG).5,6
Recently, CABG without CPB (OPCAB) was reintro-
duced in cardiac surgery, initially for selected patients and
then for an increasing number of indications.7-9 Avoidance
of CPB may reduce the prevalence of perioperative com-
plications, particularly bleeding. However, there are large
differences in terms of postoperative bleeding and alloge-
neic transfusions reported in published studies.10-12 At our
institution, prophylactic infusion of tranexamic acid (TA), a
synthetic antifibrinolytic drug with demonstrated hemostatic
properties in cardiac surgery,13 has been previously studied
in different types of patients undergoing cardiovascular
surgery with CPB,14-17 and it was also found promising in a
pilot study of patients undergoing OPCAB.18 In this study
we compared the hemostatic effects of TA in patients un-
dergoing CABG with and without CPB and evaluated the
effects of this drug on selected coagulation, fibrinolysis, and
inflammation variables.
Materials and Methods
From January 3, 2001, to June 30, 2001, consecutive patients
undergoing OPCAB and consecutive patients undergoing on-pump
CABG (ONCAB) only if three or fewer distal anastomoses were to
be performed were considered for the enrollment in the study. The
criteria for the choice of surgery were predefined. Indications for
OPCAB were as follows: single critical stenosis of the anterior
descending coronary artery, without the possibility of a catheter-
based intervention, restenosis after angioplasty or stent placement,
or multivessel coronary disease in patients for whom CPB was
contraindicated because of associated comorbid conditions (severe
chronic obstructive pulmonary disease, cerebrovascular diseases,
severe peripheral vascular disease). Exclusion criteria from the
study were history of hematologic disease, chronic renal insuffi-
ciency (creatinine level 2 mg/dL), and liver disease (active
chronic hepatitis or cirrhosis). Preoperative treatment with aspirin
or subcutaneous low–molecular weight heparin was not a contra-
indication to inclusion in the study.
A total of 102 patients were enrolled: 51 patients constituted
the OPCAB group, and 51 constituted the ONCAB group. By
means of two separate computer-generated random number se-
quences, the patients assigned to OPCAB and ONCAB were
double-blind randomly assigned to receive TA or placebo. TA was
administered as a bolus injection of 1g in 20 minutes before skin
incision, followed by a continuous infusion of 400 mg/h until
completion of surgery. Placebo consisted of an equivalent volume
of saline solution. In ONCAB surgery, 500 mg of the drug or an
equivalent volume of saline solution was added to the priming of
CPB. The staff in the operating room and the intensive care unit
(ICU) were blinded regarding treatment: the correct procedure was
ensured by means of coded syringes, prepared by a fellow in
anesthesia not directly involved in the perioperative patient care
and in the treatment of clinical data. The institutional review board
approved the study, and written informed consent was obtained
from each enrolled patient.
84 The Journal of Thoracic and Cardiovascular Surgery ● July 2A standardized protocol of anesthesia was used for all pa-
tients.18,19 All the patients were operated on through a full median
sternotomy. The left internal thoracic artery was harvested in each
patient through conventional pleurotomy access; if required, the
saphenous vein was also isolated.
ONCAB Technique
Before aortic cannulation, porcine mucous heparin (3 mg/kg) was
administered to obtain during CPB an activated clotting time
(ACT) longer than 480 seconds. The circuit for CPB included a
centrifugal pump for nonpulsatile blood flow and a hollow-fiber
membrane oxygenator. The priming solution of the circuit con-
sisted of a balanced crystalloid-colloid solution (1350 mL Ringer
lactate, 250 mL 18% mannitol, 150 mL, plasma expander). Blood
temperature was kept between 32°C and 35°C. Myocardial pro-
tection during aortic crossclamping was achieved with blood car-
dioplegia according to the Buckberg method. At the end of CPB,
the total dose of heparin administered was antagonized with pro-
tamine sulfate (1:1 ratio); if required, further doses of 50 mg were
administered to obtain an ACT value equal to or shorter than the
baseline ACT. The remaining blood in the circuit and that aspired
from the surgical field was concentrated with a cell separator and
reinfused. During the postoperative period, no autotransfusion of
mediastinal shed blood was performed.
OPCAB Technique
After the opening of the pericardium, the stabilizing system
(Medtronic-Utrecht Octopus System; Medtronic Inc, Minneapolis,
Minn) was positioned in the sternal wound. A heparin dose of 1
mg/kg was administered, and an ACT longer than 250 seconds was
maintained until the anastomoses were performed with supplemen-
tary doses of 50 mg. No drugs were administered to diminish heart
frequency. Vessel occlusion was achieved, proximally and distally,
with a 4-0 polytetrafluoroethylene suture passed through a silicone
tube to avoid the direct contact between the suture and the wall of
the coronary artery and tightened by tourniquets. After completion
of all anastomoses, the total dose of heparin administered was
antagonized with protamine sulfate (1:1 ratio); if required, further
doses of 50 mg were administered to obtain an ACT value equal to
or shorter than baseline ACT. Only in cases of significant intra-
operative bleeding was the shed blood concentrated in a cell
separator and reinfused. No postoperative autotransfusion of me-
diastinal shed blood was performed. In the absence of periopera-
tive bleeding complications patients received acetylsalicylic acid
(orally) or lysine-acetylsalicylate (intravenously), starting on the
evening of the first postoperative day.
Blood Sampling and Processing
Samples for hematochemical evaluation were obtained and ana-
lyzed as previously reported elsewhere.19 Briefly, sequential ve-
nous samples were obtained in all cases through the heparinized
distal line of the central venous catheter and collected in sili-
conized Vacutainer tubes (Becton Dickinson, Plymouth, UK) at
the following times: after the induction of anesthesia (time 1), 10
minutes after patient arrival in the ICU (time 2), and 24 hours after
the operation (time 3). All samples were obtained with a two-
syringe technique with minimal stasis: 10 mL of blood was aspired
in the first syringe and discarded, and another 10 mL was then
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Pobtained with the second syringe for hematochemical evaluation.
Within 1 hour from blood collection, platelet-poor plasma was
obtained by centrifugation for 20 minutes at 2000g at room tem-
perature. Prothrombin time (PT) and activated partial thromboplas-
tin time (APTT) were measured in fresh plasma samples. Aliquots
of platelet-poor plasma (0.5 mL) were snap-frozen and stored at
80°C until assay.
Assay Methods
All determinations of hemostatic variables were carried out with a
fully automated coagulometer (STA Diagnostica; Stago, Asnier
sur Seine, France). Reagents for APTT (STA APTT Kaolin),
fibrinogen (STA Fibrinogen), D-dimer (STA Liatest D-DI), anti-
thrombin III (amidolytic activity, STA Antithrombin III), and
2-antiplasmin (amidolytic activity, STA Antiplasmin) determina-
tions were obtained from Roche Diagnostic (Mannheim, Ger-
many). PT was measured with Hemoliance Recombiplastin IL
(Instrumentation Laboratory, Lexington Mass), and plasminogen
levels (amidolytic activity) were measured with the Coamatic kit
(substrate S-2403; Chromogenix AB, Mo¨lndal, Sweden). APTT
and PT results were expressed as ratios, with the APTT and PT
values measured in normal pooled plasma obtained from 40
healthy volunteers as denominators. The same normal pooled
plasma, arbitrarily given a value of 100%, was used to construct
calibration curves for all the amidolytic assays.
Plasma immunoglobulin G (IgG) levels were measured by
immunonephelometry (Tina-Quant IgG Kit; Boehringer Mann-
heim, Mannheim, Germany) in a Modular Hitachi 917 (Roche
Diagnostic). Interleukin (IL) 6 was measured in citrated plasma by
a commercially available enzyme-linked immunosorbent assay kit
(Amersham Pharmacia Biotech UK Limited, Buckinghamshire,
UK).
Criteria for Allogeneic Transfusion and Surgical
Reexploration
Patients were transfused only in the presence of signs or symptoms
of hypovolemia (hypotension or tachycardia) or diffuse bleeding.
Perioperative criteria for allogeneic transfusions were standard-
ized: in both groups packed red blood cells were transfused if the
hemoglobin value was less than 8 g/dL or the hematocrit was less
than 24% . Fresh-frozen plasma was infused if the PT value after
protamine administration was at least 1.5 times the baseline, and
platelet concentrates were transfused with platelet counts of
50,000/mm3 or less.
Blood loss was recorded during the first 24 hours, and exces-
sive bleeding was defined as a blood loss greater than 600 mL in
24 hours. Chest drains were removed when bleeding was less than
100 mL in the preceding 4 hours. Surgical reexploration occurred
when bleeding in the first 2 hours was greater than 300 mL/h, or
when it was greater than 200 mL/h for 4 consecutive hours, with
normal coagulation variables.
Secondary Outcomes
During the first 24 postoperative hours, possible thrombotic com-
plications as consequence of antifibrinolytic therapy were re-
corded. These were myocardial infarction (new Q waves at elec-
trocardiography, creatine kinase MB isoenzyme ratio greater than
10%, and troponin I 0.1 ng/dL), acute renal insufficiency (cre-
The Journal of Thoracatinine value twice the baseline or need for dialysis), major neu-
rologic dysfunction (transient ischemic attack or stroke), deep
venous thrombosis, and pulmonary embolism.
Statistical Methods
Considering as primary outcome the effects of TA on postopera-
tive bleeding, the trial was designed to detect a difference of 200
mL in postoperative bleeding (SD 250 mL) between the groups
undergoing the same surgical approach. This design was based on
data emerging from a previous study.14 To achieve significance, 25
patients per group were required, with a 1-tailed  error of .05 and
80% power. Analysis was conducted on an intent-to-treat basis.
Normality of the distribution of continuous variables was eval-
uated with the Kolmogorov-Smirnov test. Data are reported as
mean  SD or median with interquartile range (25-75th percen-
tile). Comparisons in continuous variables between patients ran-
domly assigned to treatment in the two surgical groups were
performed by analysis of variance after log transformation of
nonnormally distributed variables. The 2 test, the Fisher exact
test, or Mantel-Haenszel odds ratios (adjusted for the surgical
techniques) were used for comparisons of discrete variables.
The changes in hematochemical variables were evaluated by
analysis of variance for repeated measures after log transformation
of nonnormally distributed variables, including treatment and sur-
gical technique as factors and preoperative values as covariate.
Analysis was conducted on both unadjusted data and data adjusted
for hemodilution according to the following formulas: [IgG]initial
 [IgG]timepoint/[IgG]initial for hematochemical variables and He-
matocritinitial  Hematocrittimepoint/Hematocritinitial for platelet
counts. IgG levels were chosen as an indicator of hemodilution
because they are not affected by surgery and are not involved in
metabolic pathways altered early by trauma. Bonferroni correction
was applied for post hoc comparisons.
Results
All patients completed the study. Two patients scheduled
for OPCAB (1 in each treatment group) required conversion
to ONCAB because of hemodynamic instability during the
maneuvers of exposition of coronary vessels, but these cases
were analyzed on an intent-to-treat basis and included in the
OPCAB group.
Baseline characteristics and operative data are shown in
Tables 1 and 2. There were no significant differences for
patients assigned to TA or placebo within each surgical
group. Patients undergoing OPCAB had lower left ventric-
ular ejection fraction (P  .004) and higher Higgins score20
(P  .0004) than did those undergoing ONCAB (Table 1).
Surgical time was significantly longer for ONCAB than for
OPCAB (P  .001), and higher doses of heparin and
protamine were used in ONCAB (P  .0001).
The extent of postoperative bleeding and the requirement
for allogeneic transfusions are shown in Table 3. As ex-
pected, blood losses were higher in patients undergoing
ONCAB than in those undergoing OPCAB (P  .007), but
TA reduced early bleeding and 24-hour bleeding in both
groups (P  .0001). There was a trend toward a greater
ic and Cardiovascular Surgery ● Volume 128, Number 1 85
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(52% vs 22%, P  .052), but total postoperative bleeding
was reduced to a similar extent in both groups (43% vs 27%,
P  .9). In addition, relative to placebo-treated patients,
patients who received TA had a much lower probability of
bleeding in excess of 600 mL in the first 24 postoperative
hours (Mantel-Haenszel odds ratio 0.18, 95% confidence
interval 0.08-0.43). The rate of bleeding was not influenced
by preoperative low–molecular weight heparin treatment,
irrespective of the type of surgery and TA treatment (data
TABLE 1. Demographic and baseline characteristics of pa
Variable
OPCAB
Placebo
(n  25)
Age (y, mean  SD) 61 11 6
Male sex (No.) 21 (84%) 2
Height (cm, mean  SD) 169 7 16
Weight (kg, mean  SD) 73 10 7
Baseline left ventricular ejection
fraction (%, mean  SD)
46 13 4
Previous acute myocardial
infarction (No.)
17 (68%) 1
Coexisting illness (No.)
Hypertension 7 (28%)
Diabetes 5 (20%)
Peripheral vascular disease 3 (12%)
Chronic obstructive pulmonary
disease
2 (8%)
Higgins score (median and
interquartile range)
3 (2-6)
Preoperative aspirin, n (%) 7 (28%)
Preoperative low–molecular
weight heparin (No.)
3 (12%)
*P value for comparison of four groups.
†P  .0001 for OPCAB versus ONCAB.
TABLE 2. Operative data
Variable
OPCAB
Placebo
(n  25)
TA
(n  2
Resternotomy (No.) 2 (8%) 3 (11.5
CPB time (min) 0 (0-0) 0 (0-0)
Aortic crossclamp time
(min)
0 (0-0) 0 (0-0)
Surgical time (min) 165 (122-193) 178 (124
Distal anastomoses 2 (1-3) 2 (1-3)
Total heparin dose (mg) 80 (70-100) 80 (71-9
Total protamine dose
(mg)
80 (70-100) 80 (71-1
Except as indicated, all values are median and interquartile range.
*P value for comparison of four groups.
†P  .0001 for OPCAB versus ONCAB.not shown). Among patients undergoing ONCAB there
86 The Journal of Thoracic and Cardiovascular Surgery ● July 2were 1 reexploration for bleeding in the TA group and 3 in
the placebo group (odds ratio 0.21, P  .38). A surgical
source of bleeding was identified at reexploration in 2
patients (1 in TA group and 1 in placebo group). Consistent
with these findings, the number of patients requiring allo-
geneic transfusions was lower in the TA group, although
this difference did not reach statistical significance. The
amount of packed red blood cell units transfused, which was
significantly higher in patients undergoing ONCAB than in
those undergoing OPCAB (P  .0001), and the numbers of
s undergoing CABG
ONCAB
P value*26)
Placebo
(n  25)
TA
(n  26)
12 60 9 64 9 .41
.9%) 21 (84%) 24 (92.3%) .85
9 171 6 172 6 .18
12 77 9 77 12 .08
14 52 11 50 11 .023†
.1%) 13 (52%) 11 (42.3%) .9
.4%) 8 (30.8%) 6 (23%) .55
.2%) 6 (24%) 4 (15.4%) .89
%) 2 (8%) 3 (11.5%) .70
%) 4 (16%) 2 (7.7%) .71
6) 1 (0-2) 2 (1-3) .0012†
.1%) 7 (28%) 6 (23.1%) .95
.4%) 5 (20%) 4 (15.4%) .35
ONCAB
P value*
Placebo
(n  25)
TA
(n  26)
3 (12%) 4 (15.4%) .88
90 (62-116) 83 (60-96) .0001†
65 (44-88) 59 (43-85) .0001†
234 (185-275) 227 (183-247) .001†
2 (2-3) 2 (2-3) .35
240 (220-270) 240 (210-258) .0001†
250 (240-300) 250 (220-300) .0001†tient
TA
(n 
4
0 (76
8
1
3
9 (73
4 (15
5 (19
1 (3.8
2 (7.7
3 (2-
6 (23
4 (156)
%)
-243)
8)
00)fresh-frozen plasma and platelet concentrate units trans-
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Pfused were reduced by 40%, 80%, and 50% in the TA
group, with a total number of 54 units in the TA group
versus 91 in the placebo group (P  .07).
Intubation time (median 10 hours, interquartile range
7-13 hours), ICU stay (median 1 day, interquartile range 1-2
days), hospital stay (median 8 days, interquartile range 6-10
days), and the percentages of patients requiring major ino-
tropic therapy (9%) or mechanical ventilation for longer
than 48 hours (5%) or with postoperative atrial fibrillation
(24%), myocardial infarction (4%), or renal insufficiency
(2.5%) were similar in the four groups of patients (in all
cases P  .3). No patients had stroke or clinical pulmonary
embolism. Two patients died in the OPCAB group (1 in
each treatment group), and 1 died in the CABG placebo
group (P  .5).
The changes in hematochemical variables (unadjusted
for hemodilution) are reported in Table 4. Baseline levels of
the variables considered were similar in all patient groups
(P  .2). With the exception of PT and APTT values (not
shown), all variables showed significant variations with
time. Changes in hemoglobin, hematocrit, fibrinogen, anti-
thrombin III, and 2-antiplasmin were influenced only by
the surgical technique. With the exception of 2-antiplas-
min, all these values decreased after the operation (P 
.0001), but they decreased to a greater extent in patients
undergoing ONCAB than in those undergoing OPCAB (P
 .01) and were still lower in patients who underwent
ONCAB 24 hours after the operation (P  .0001). Platelet
counts decreased to a significant extent after the operation
only in patients undergoing ONCAB (P  .0001), and they
TABLE 3. Postoperative bleeding and perioperative alloge
Variable
OP
Placebo
(n  25)
Bleeding in first 4 h (mL, median and
interquartile range)
311 (255-450)
Total bleeding in 24 h (mL, median and
interquartile range)
654 (510-820)
Excessive bleeding (No.) 15 (60%)
Reexploration for bleeding (No.) 0
Transfusions with packed red blood cells
(No.)
4 (16%)
Total packed red blood cells (units) 11
Transfusions with fresh-frozen plasma (No.) 2 (8%)
Total fresh-frozen plasma (units) 10
Transfusions with platelet concentrate (No.) 0 (0%)
Total platelet concentrate (units) 0
Bleeding was defined excessive for losses greater than 600 mL in the firs
*P value for comparison of four groups.
†P  .0001 for OPCAB versus ONCAB, P  .0001 for TA versus placebo.
‡P  .007 for OPCAB versus ONCAB, P  .0001 for TA versus placebo.
§P  .0001 for TA versus placebo.were still lower 24 hours after the operation in these patients
The Journal of Thorac(P  .0001). Both treatment and type of surgery influenced
the changes in the other variables examined. Plasminogen
levels decreased significantly in all patient groups after the
operation (P .0001), but they decreased to a greater extent
in those treated with TA (P  .0001) and in those under-
going ONCAB (P  .0001), and they were still lower in
these patients 24 hours after the operation (P  .001).
D-dimer levels increased after the operation only in
patients receiving placebo (P  .0001), and to a greater
extent in those undergoing ONCAB (P  .0001). The day
after the operation, D-dimer levels were still lower in pa-
tients treated with TA (P  .0001), irrespective of the
surgical technique. IgG levels decreased in all patients after
the operation (P  .02), and they did so to a greater extent
in patients undergoing ONCAB (P  .0001) and in those
receiving placebo (P  .005). The day after the operation,
IgG levels were still lower in patients undergoing ONCAB
(P .0001) and in patients treated with placebo (P .025).
IL-6 levels increased in all patients after the operation, but
they decreased to a greater extent in patients undergoing
ONCAB (P  .0001) and to a lesser extent in patients
receiving TA (P  .0001). In addition, modulation of IL-6
levels by TA was greater in patients undergoing OPCAB (P
 .001). Twenty-four hours after the operation, IL-6 levels
were still lower in patients undergoing OPCAB and in those
treated with TA (P  .001).
After correction for hemodilution, antithrombin III and
fibrinogen levels decreased to similar extents in patients
undergoing OPCAB and ONCAB, irrespective of treatment
(data not shown). Changes in selected hemostatic variables
transfusions
ONCAB
P value*
TA
(n  26)
Placebo
(n  25)
TA
(n  26)
50 (100-190) 352 (310-550) 275 (223-338) .0001†
75 (356-550) 754 (550-1200) 552 (422-704) .0001‡
3 (11.5%) 17 (68%) 10 (38.5%) .0005§
0 3 (12%) 1 (3.9%) .57
3 (11.5%) 9 (36%) 6 (23.1%) .41
6 32 23 .0001†
0 (0%) 4 (16%) 1 (3.9%) .13
0 24 18 .88
0 (0%) 2 (8%) 1 (3.9%) .28
0 14 7 .99
ostoperative hours.neic
CAB
1
3
t 24 padjusted for hemodilution are shown in Figure 1. Irrespec-
ic and Cardiovascular Surgery ● Volume 128, Number 1 87
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CSP tive of treatment, platelet counts decreased after the opera-tion only in patients undergoing ONCAB (P  .0001),
whereas, irrespective of type of surgery, plasminogen and
2-antiplasmin levels were lower after the operation in
patients receiving TA (P  .0001). In addition, 2-antiplas-
min levels were higher in patients undergoing ONCAB than
in those undergoing OPCAB (P  .037). D-dimer levels
were higher after the operation in patients receiving placebo
(P  .001) and in those undergoing ONCAB (P  .002).
Fibrinogen and 2-antiplasmin levels 24 hours after the
operation (adjusted for hemodilution) were strongly associ-
ated with IL-6 levels measured at the end of the procedure
(unadjusted for hemodilution, P  .0001). Mirroring IL-6
levels, both variables were higher in patients undergoing
ONCAB (P  .0001) and in those treated with placebo (P
 .0001), with the modulating effect of TA more pro-
nounced in patients undergoing OPCAB (P  .01, Figure
2).
Discussion
Perioperative hemorrhagic disorders remain the most com-
mon complication in cardiac surgery performed with CPB,
TABLE 4. Postoperative changes in laboratory variables
Group
OPCAB
Time 1 Time 2 Time 3 Time
Hemoglobin
(g/dL)
Placebo 14.6 1.6 12.6 1.3 11.8 1.5 14.6
TA 13.5 1.8 11.3 1.4 11.5 1.5 14.2
Hematocrit
(%)
Placebo 43.4 3.8 37.8 3.4 35.4 4.3 43.0
TA 40.2 4.8 34.2 4.2 34.7 3.7 42.2
Platelets (103
cells/mm3)
Placebo 223 86 193 82 188 83 201
TA 217 100 186 89 188 65 202
Fibrinogen
(mg/dL)
Placebo 363 79 293 67 425 81 353
TA 328 87 278 92 378 98 337
D-dimer (mg/L,
median and
interquartile
range)
Placebo 0.74
(0.44-1.73)
0.84
(0.50-1.15)
1.35
(0.73-2.36)
0.61
(0.48-1
TA 0.46
(0.34-0.89)
0.41
(0.22-0.68)
0.51
(0.29-1.27)
0.66
(0.35-0
Antithrombin III
(%)
Placebo 83 16 67 12 69 11 85
TA 78 12 64 13 68 9 82
Plasminogen
(%)
Placebo 99 17 83 17 79 20 100
TA 93 17 69 23 70 16 95
2-antiplasmin
(%)
Placebo 89 10 71 12 86 10 91
TA 82 14 69 16 78 15 88
IL-6 (pg/mL,
median and
interquartile
range)
Placebo 0.8
(0-2.2)
44
(22-87)
73
(36-134)
1.7
(0-8.
TA 2.3
(0.8-5.6)
23
(10-61)
76
(50-92)
0.5
(0-5.
IgG (g/L) Placebo 8.0 2.1 6.4 1.3 6.3 1.4 7.7
TA 7.5 1.7 6.6 1.9 6.5 1.6 8.1
All values are mean  SD unless otherwise specified. Time 1, After induct
surgery; TA, tranexamic acid.mainly because of activation and consumption of platelets
88 The Journal of Thoracic and Cardiovascular Surgery ● July 2and hyperfibrinolysis.3-5 OPCAB has been recently reintro-
duced into surgical practice, with the potential advantage of
reducing the hemostatic alterations resulting from CPB.
However, these alterations are probably only partially de-
pendent on contact activation during CPB, because activa-
tion of the extrinsic pathway of coagulation has been re-
ported a major trigger for thrombin formation in cardiac
surgery.5,21 Thus although a number of studies have docu-
mented significant reduction in perioperative bleeding and
in the need for allogeneic transfusions with OPCAB, this
improvement has occurred to a variable extent. Ascione and
coworkers11 reported significant reduction in postoperative
blood loss, transfusion requirement, and transfusion-related
costs for patients undergoing OPCAB, but Van Dijk and co-
workers12 reported a difference of only 90 mL in terms of
bleeding between patients undergoing OPCAB and ONCAB,
without any difference in the percentage of patients transfused.
One of the most common blood-sparing maneuvers in
cardiac surgery is the use of drugs with antifibrinolytic
properties, such as aprotinin, -aminocaproic acid, and
TA.13 At our institution TA is widely used in patients
undergoing surgery with CPB.14-17 In a previously pub-
ONCAB Analysis of variance for repeated measures
Time 2 Time 3 Time
Time 
treatment
Time 
surgery
Time 
treatment
 surgery
11.5 1.4 11.0 1.4 .0001 .21 .025 .09
11.6 1.4 11.4 1.3
34.6 4.1 33.7 5.5 .001 .41 .035 .12
34.9 4.2 34.4 4.1
119 33 128 44 .34 .19 .0001 .27
138 36 153 72
231 69 360 83 .0001 .60 .0001 .09
231 58 385 91
2.31
(1.76-3.72)
1.18
(0.72-1.58)
.20 .0001 .0001 .001
0.51
(0.31-0.92)
0.65
(0.49-0.92)
58 12 62 12 .001 .09 .001 .59
61 10 66 12
73 13 72 20 .12 .001 .001 .94
58 12 61 15
63 15 77 19 .0001 .95 .002 .07
61 14 82 15
126
(68-229)
54
(30-81)
.0001 .045 .0001 .49
103
(45-165)
68
(34-89)
5.5 1.8 4.9 1.0 .02 .003 .0001 .271
5.9 1.5 5.8 1.6
f anesthesia; Time 2, 10 minutes after arrival in ICU; Time 3, 24 hours after1
1.1
0.9
3
2.8
54
58
81
80
.02)
.88)
8
13
18
16
20
15
1)
7)
1.4
2.1
ion olished pilot study, we tested the effects of TA in patients
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CS
PFigure 2. IL-6 levels (A) at time 2 (after arrival in ICU, unadjusted for hemodilution) and fibrinogen levels (B) and
2-antiplasmin levels (C) at time 3 (24 hours after end of operation) in patients undergoing OPCAB or ONCAB and
receiving placebo or TA. Box plots with medians (horizontal lines), interquartile ranges (boxes), and 95%
confidence intervals (vertical lines) are shown. Diagonal fills slanting downward from right represent OPCAB and
placebo; white fills represent OPCAB and TA; diagonal fills slanting downward from right represent ONCAB and
placebo; black fills represent ONCABG and TA. P values refer to analysis of variance for repeated measures (seeFigure 1. Changes (adjusted for hemodilution) in platelet counts (A), D-dimer levels (B), plasminogen levels (C), and
2-antiplasmin levels (D) in patients undergoing OPCAB or ONCAB and receiving placebo or TA at time 1 (after
induction of anesthesia), time 2 (10 minutes after arrival in ICU), and time 3 (24 hours after end of operation). Box
plots with medians (horizontal lines), interquartile ranges (boxes), and 95% confidence intervals (vertical lines) are
shown. Diagonal fills slanting downward from right represent OPCAB and placebo; white fills represent OPCAB
and TA; diagonal fills slanting downward from right represent ONCAB and placebo; black fills represent ONCABG
and TA. P values refer to analysis of variance for repeated measures (see text for explanation). ns, Not
significant.text for explanation).
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CSPundergoing OPCAB, showing reduction in postoperative
bleeding and in the requirement for allogeneic transfu-
sions.18 This is the first double-blind study to compare the
effects of TA treatment on clinical and laboratory variables
in patients undergoing OPCAB and ONCAB. Our pharma-
cologic protocols for TA reduced by 30% to 50% early and
24-hour postoperative blood losses both in patients under-
going OPCAB and in those undergoing ONCAB. Accord-
ingly, the probability of bleeding exceeding 600 mL in the
first postoperative day was reduced 80% by TA. Because of
the insufficient sample size, we could not show a significant
reduction in the requirement for allogeneic transfusions,
which were, however, between 40% and 80% lower in
patients treated with TA, irrespective of the type of surgery.
Reduced bleeding was not counterbalanced by an increased
rate of postoperative thrombotic complications, although
our study was not powered adequately to examine this issue.
We have previously shown that both OPCAB and ON-
CAB are associated with a net consumption of antithrombin
III and fibrinogen, whereas transient decrease in platelet
count, greater plasminogen activation, and increased D-
dimer formation are only observed with ONCAB.19 TA
binds to the high-affinity lysine-binding sites of plasmino-
gen and plasmin, preventing binding to fibrin and the re-
sulting fibrin proteolysis.22 At least in vitro, however, plas-
minogen activation is paradoxically accelerated, because
TA binding alters the conformation of plasminogen so that
it becomes more susceptible to proteolytic activation by
activators.23 The ex vivo data reported in this article are
consistent with these findings. Whereas the changes in fi-
brinogen, antithrombin III, and platelet counts were not
affected, TA prevented postoperative increase in D-dimer
levels both in patients undergoing ONCAB and in those
undergoing OPCAB to a substantial extent. After correction
for hemodilution, however, plasminogen and 2-antiplas-
min levels were lower after the operation in patients receiv-
ing TA, suggesting increased in vivo plasminogen activa-
tion to plasmin, complex formation with 2-antiplasmin,
and clearance. In vivo inhibition of fibrinolysis by TA has
been previously reported.24,25 With dosages of TA lower
than those administered to our patients, Horrow and asso-
ciates24 observed a significant reduction in plasminogen
levels, whereas Blauhut and coworkers25 observed reduced
2-antiplasmin but not plasminogen levels in cardiac surgi-
cal patients.
In a study of patients undergoing ONCAB, aprotinin but
not -aminocaproic acid reduced IL-10 and IL-6 levels
relative to placebo.26 We show for the first time an anti-
inflammatory effect of TA treatment in patients undergoing
CABG. As expected, CPB induced a greater response in
IL-6 levels than that observed in patients undergoing OP-
CAB; however, postoperative increase in IL-6 was lower in
patients treated with TA. TA may modulate the inflamma-
90 The Journal of Thoracic and Cardiovascular Surgery ● July 2tory response related to tissue damage and to the activation
of the coagulation system to a greater extent in the presence
of “low-grade” inflammation, such as occurs after OPCAB,
than in the ONCAB setting. Because of the positive feed-
back between inflammation and coagulation, control of in-
flammation may reduce postoperative hypercoagulability
and potentially affect the rate of thrombotic complications.
Twenty-four hours after the operation, fibrinogen and 2-
antiplasmin—two acute-phase reactants—were lower in our
patients treated with TA and correlated with postoperative
IL-6 levels.
In conclusion, this study indicates that TA is effective in
reducing bleeding through the prevention of secondary fi-
brinolysis both in patients undergoing ONCAB and in those
undergoing OPCAB. Further randomized studies, enrolling
larger numbers of patients, are needed to confirm the anti-
inflammatory effects of TA and to rule out the potential risk
of thrombotic complications.
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